Berberine
Berberine is an isoquinoline alkaloid found in several plants, with high concentrations in goldenseal, coptis, Oregon grape, barberry and tree turmeric. It is sold over the counter alone and in multi-ingredient dietary supplements.
- Category
- Other
- Forms
- Isolated alkaloid, sold alone or in multi-ingredient supplements
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-28
Class 1 Well studied in people. A 2023 meta-analysis (Drugs) included 18 randomized placebo-controlled trials (1,788 adults) of berberine for blood lipids, conducted mainly in mainland China and Hong Kong, and pooled up to 18 of them. [4]
Fact-checked 2026-10-28 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BHeart and blood vessels2 topics
BBlood sugar and weight2 topics
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Blood glucose in type 2 diabetes | B | NCCIH reports some evidence of a modest blood glucose-lowering effect in people with type 2 diabetes. [1] |
| Cholesterol | B | NCCIH reports some evidence that berberine may lower cholesterol. [1] |
| Body weight | C | Evidence comes mainly from preliminary studies with few clinical trials in people; NCCIH finds not enough rigorous evidence to judge effectiveness. [1] |
| Blood pressure (with amlodipine) | C | NCCIH reports berberine may offer additional benefit when combined with the blood pressure drug amlodipine. [1] |
Main constituents: Berberine (isoquinoline alkaloid) [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Usual recommended dose of the herbal product: 250 to 500 mg two or three times daily (LiverTox). [2]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Score EABCDEA: well known causeE: unlikely cause
LiverTox likelihood score E: unlikely cause of clinically apparent liver injury (chapter last updated October 6, 2020).
Details and sources - Pregnancy and breastfeedingNCCIH: people who are pregnant or breastfeeding should not use berberine …
1 statement in the profile.
Details and sources - Interactions with medicines2 listed
Medicines in general; CYP3A substrates (e.g. midazolam)
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- Generally well tolerated orally; common side effects are abdominal pain, constipation, diarrhea, nausea and vomiting. [1]
- People who are pregnant or breastfeeding should not use berberine. It should not be given to infants: it can cause or worsen newborn jaundice and may lead to kernicterus, a life-threatening condition. [1]
- LiverTox likelihood score E (unlikely cause of clinically apparent liver injury); no published cases despite wide use. [2]
Interactions
| With | What happens |
|---|---|
| Medicines in general | NCCIH warns that berberine might interact with medicines in harmful ways. [1] |
| CYP3A substrates | Berberine is a time-dependent CYP3A inhibitor in human liver microsomes (laboratory finding); in goldenseal, (-)-β-hydrastine was the main contributor to the clinical midazolam interaction. [3] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Regulatory status
- US: sold over the counter alone and in multi-ingredient dietary supplements. [2]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Berberine Isoquinoline alkaloid (a quaternary ammonium compound) [P2]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming berberine was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P5]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- LiverTox likelihood score E: unlikely cause of clinically apparent liver injury (chapter last updated October 6, 2020). [P2]
Interactions with medicines
- Medicines in general: NCCIH: berberine might interact with medicines in harmful ways. [P1]
- CYP3A substrates (e.g. midazolam): Berberine was identified as a time-dependent CYP3A inhibitor in human liver microsomes (laboratory finding). In human intestinal microsomes it was a much weaker time-dependent inhibitor than (-)-β-hydrastine, and modeling implicated (-)-β-hydrastine as the main driver of the clinical goldenseal-midazolam interaction (40%-60% rise in midazolam AUC with goldenseal). [P3]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- Label accuracy (2018 study of 15 US berberine supplements, UHPLC-MS/MS): average content was 75% ± 25% of the label claim (range 33% to 100%); 9 of 15 products (60%) fell outside 90%-110% of the labeled content. Measured potency was not associated with price. [P4]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each dietary-ingredient component — US cGMP rule for dietary supplements: at least one appropriate test or examination must verify the identity of any component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)); exemption only through a petition FDA grants (111.75(a)(1)(ii)). [P6]
- Berberine assay against label claim (e.g. UHPLC-MS/MS) — 60% of tested US products failed a 90%-110% of label claim potency range. [P4]
Supply and conservation
- Plant sources named by LiverTox: berberine is found in many plants and in particularly high concentrations in Hydrastis canadensis (goldenseal), Coptis chinensis (coptis or goldenthread), Berberis aquifolium (Oregon grape), Berberis vulgaris (barberry) and Berberis aristata (tree turmeric). [P2]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- NCCIH: people who are pregnant or breastfeeding should not use berberine; it should not be given to infants because it can cause or worsen newborn jaundice and may lead to kernicterus. [P1]
Sources for this profile
- NCCIH. In the News: Berberine (Last Updated: June 2023), 2023-06. nccih.nih.gov
- NIH LiverTox (NIDDK). Berberine (Last Update: October 6, 2020), 2020-10-06. ncbi.nlm.nih.gov
- Nguyen JT, et al. An integrative approach to elucidate mechanisms underlying the pharmacokinetic goldenseal-midazolam interaction. J Pharmacol Exp Ther 2023;387(3):252-264 (PMID 37541764), 2023-12. pubmed.ncbi.nlm.nih.gov
- Funk RS, et al. Variability in potency among commercial preparations of berberine. J Diet Suppl 2018;15(3):343-351 (PMID 28792254), 2018-05-04. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of October 23, 2026), 2026-10-23. ecfr.gov
- IARC Monographs. List of Classifications (retrieved October 29, 2026), 2026-10-29. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (list retrieved October 29, 2026), 2026-10-29. ntp.niehs.nih.gov
Sources
- NCCIH. Berberine: what the science says (Last Updated: June 2023), 2023-06. nccih.nih.gov
- NIH LiverTox. Berberine (last update October 6, 2020), 2020-10-06. ncbi.nlm.nih.gov
- Nguyen JT, et al. An integrative approach to elucidate mechanisms underlying the pharmacokinetic goldenseal-midazolam interaction. J Pharmacol Exp Ther 2023;387(3):252-264 (MEDLINE record), 2023-12. pesquisa.bvsalud.org
- Blais JE, et al. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Drugs 2023;83(5):403-427 (PMID 36941490), 2023-03-21. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in this category: Alpha-lipoic acid · Bee pollen · Beetroot juice (dietary nitrate) · Beta-glucan (oat and barley) · Betaine (trimethylglycine) · Bromelain · Caffeine · Choline · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.